[
  {
    "title": "Industry Outlook 2026: Biopharma Industry ... | BioPharm International",
    "url": "https://www.biopharminternational.com/view/industry-outlook-2026-biopharma-industry-confronts-skills-shortage-with-strategic-automation-part-2-",
    "domain": "www.biopharminternational.com",
    "lang": "en",
    "type": "Report",
    "summary": "Industry Outlook 2026: Biopharma Industry Confronts Skills Shortage with Strategic Automation (Part 2)\nBiopharma manufacturing faces a global workforce crisis, driving adoption of continuous upstream automation to protect and scale capacity, says Eric Langer of BioPlan Associates, in the continuation of his industry outlook.\n*Full transcript available below\nThe industry’s rapid growth—especially in\nToday, he notes, a significant share of facilities cannot fill critical roles:"
  },
  {
    "title": "Report : Positive outlook for big pharma in 2017 | BioPharma Dive",
    "url": "https://www.biopharmadive.com/news/pharma-2017-outlook-ma-market/432779/",
    "domain": "www.biopharmadive.com",
    "lang": "en",
    "type": "Report",
    "summary": "Dive Brief:\n- Poor near-term growth, pressure on foreign exchange rates from a strengthening U.S. dollar and political overhang are just a few of the things Jefferies analyst Jeffrey Holford thinks could weaken the pharma sector in 2017.\n- Even so, the analyst still anticipates plenty of R&D catalysts in the coming year and highlighted the potential for strong M&A in a December report.\n- Holford rates AbbVie and Eli Lilly as the top picks for U.S."
  },
  {
    "title": "2014 Biopharma cold-chain forecast | Pharmaceutical Commerce",
    "url": "https://www.pharmaceuticalcommerce.com/view/2014-biopharma-cold-chain-forecast",
    "domain": "www.pharmaceuticalcommerce.com",
    "lang": "en",
    "type": "Report",
    "summary": "- Pharmaceutical Commerce - May/June 2014\n2014 Biopharma cold-chain forecast\nGlobal industry will spend $8.36 billion on cold chain logistics this year\nFig. 1. Overall trend for biopharma and biopharma cold-chain product sales."
  },
  {
    "title": "Experts struggle to predict trial outcomes — and tend to be too...",
    "url": "https://www.statnews.com/2018/01/22/clinical-trials-forecasting-outcomes/",
    "domain": "www.statnews.com",
    "lang": "en",
    "type": "Report",
    "summary": "If researchers were better at forecasting the results of clinical trials — and, say, could avoid having to run trials that will inevitably fail — more resources could be devoted to trials that might succeed.\nBut, it turns out, researchers might not be great at determining the likelihood of a trial’s success."
  },
  {
    "title": "The biopharma outlook for 2025: Opportunities and challenges",
    "url": "https://pharmaphorum.com/market-access/biopharma-outlook-2025-opportunities-and-challenges",
    "domain": "pharmaphorum.com",
    "lang": "en",
    "type": "Report",
    "summary": "The biopharma outlook for 2025: Opportunities and challenges\nWith the Federal Reserve poised to implement interest rate cuts (albeit fewer than earlier forecasts assumed) and FTC leadership turnover anticipated, there may be broader shifts in how capital is both sourced and used in the biopharma industry."
  }
]